Pharmaceutical

Digital cognitive assessments and blood-based biomarkers in Alzheimer’s research

Apr 4, 2025 - 06:00
Digital cognitive assessments and blood-based biomarkers in Alzheimer’s research

Read the original article

Tags:

Previous Article

NBE Therapeutics opens ADC research facility in Switzerland

Next Article

FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA grants fast track designation for Verastem’s NSCLC therapy

FDA grants fast track designation for Verastem’s NSCLC ...

Jan 19, 2024

STAT+: Brigham and Women’s exec opens up about the Dana-Farber Cancer Institute split, and what it means for the future of cancer care

STAT+: Brigham and Women’s exec opens up about the Dana...

Sep 28, 2023

Santhera’s DMD therapy Agamree approved for NHS use after new price deal

Santhera’s DMD therapy Agamree approved for NHS use aft...

Dec 11, 2024